Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05371860 | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response | withdrawn | Phase 2 | 0 | Armando GiulianoOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04170335 | Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients | withdrawn | — | 0 | The Cleveland ClinicOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05365243 | A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads | withdrawn | N/A | 0 | Cooler Heads Care Inc.OTHER_GOV | 1 | Aug 15, 2023 | clinicaltrials |
| NCT00455039 | INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of New MexicoOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04901299 | Fulvestrant + Neratinib In Breast Cancer(HER2-Signal) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05809895 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer(AdvanTIG-211) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05191004 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05255666 | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 11, 2023 | clinicaltrials |
| NCT04896320 | Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.(2019-101826) | withdrawn | Phase 1 / Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT04675450 | NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy | withdrawn | Phase 2 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 0 | Jun 8, 2023 | clinicaltrials |
| NCT04190433 | Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT04535492 | Technology-Based Cancer Screening Intervention | withdrawn | N/A | 0 | Medical University of South CarolinaOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT04872608 | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT04350957 | Low-dose Imaging Technique (LITE) | withdrawn | N/A | 0 | University of ChicagoOTHER | 0 | Apr 26, 2023 | clinicaltrials |
| NCT05338281 | NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT(NPWTinDIEP) | withdrawn | N/A | 0 | Western University, CanadaOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT03121989 | Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy(LABC) | withdrawn | Phase 1 | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05079360 | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Veru Inc.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04252768 | A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel(AIPAC-002) | withdrawn | Phase 1 | 0 | Immutep S.A.S.INDUSTRY | 0 | Mar 22, 2023 | clinicaltrials |
| NCT04826016 | POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer(POLTER) | withdrawn | Phase 1 / Phase 2 | 0 | MedSIROTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | withdrawn | — | 0 | Global BioClinicalINDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02067416 | PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer | withdrawn | Phase 2 | 0 | Jenny C. Chang, MDOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05533320 | Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Feb 2, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT03666819 | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 6, 2023 | clinicaltrials |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 0 | Jan 6, 2023 | clinicaltrials |
| NCT04316169 | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT04291950 | Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women | withdrawn | — | 0 | University of ArizonaOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05233696 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04268693 | Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer(EDC-TNBC) | withdrawn | — | 0 | George Washington UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT01257932 | Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging | withdrawn | — | 0 | University of California, IrvineOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01277263 | Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging | withdrawn | — | 0 | University of California, IrvineOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05523063 | Effect of Physical Activity in Patients With Breast Cancer.(APACAM) | withdrawn | — | 0 | Hospices Civils de LyonOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT04535895 | Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy | withdrawn | N/A | 0 | Medical University of GrazOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02514837 | Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer(RTM) | withdrawn | — | 0 | University of EdinburghOTHER | 0 | Aug 19, 2022 | clinicaltrials |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | withdrawn | N/A | 0 | Xoft, Inc.INDUSTRY | 0 | Aug 2, 2022 | clinicaltrials |
| NCT04685551 | Improving Survivorship Among Minority Cancer Dyads | withdrawn | N/A | 0 | Charles Drew University of Medicine and ScienceOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02569489 | Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer | withdrawn | Phase 1 | 0 | HUYABIO International, LLC.INDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | Jul 11, 2022 | clinicaltrials |
| NCT02562612 | Study of SM-88 in Advanced Cancers | withdrawn | Phase 1 / Phase 2 | 0 | Tyme, IncINDUSTRY | 0 | Jul 1, 2022 | clinicaltrials |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases(TOPAZ) | withdrawn | Phase 1 / Phase 2 | 0 | Reva BashoOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02035085 | 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction(CS-1000) | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT04630210 | Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity(AteBrO) | withdrawn | Early Phase 1 | 0 | Universitaire Ziekenhuizen KU LeuvenOTHER | 0 | Jun 15, 2022 | clinicaltrials |
| NCT04560439 | Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05244434 | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05005936 | Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | May 27, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 22, 2023source: clinicaltrials